WO2003061715A1 - Infection-resistant medical devices - Google Patents

Infection-resistant medical devices Download PDF

Info

Publication number
WO2003061715A1
WO2003061715A1 PCT/US2003/001710 US0301710W WO03061715A1 WO 2003061715 A1 WO2003061715 A1 WO 2003061715A1 US 0301710 W US0301710 W US 0301710W WO 03061715 A1 WO03061715 A1 WO 03061715A1
Authority
WO
WIPO (PCT)
Prior art keywords
medical device
oxazolidinone
linezolid
mic
adherence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/001710
Other languages
English (en)
French (fr)
Inventor
John Kenneth Gibson
Charles W. Ford
Paul J. Pagano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003561656A priority Critical patent/JP2005515029A/ja
Priority to MXPA04007067A priority patent/MXPA04007067A/es
Priority to KR10-2004-7011249A priority patent/KR20040077753A/ko
Priority to CA002469665A priority patent/CA2469665A1/en
Priority to EP03732006A priority patent/EP1467773A1/en
Priority to HK05105508.9A priority patent/HK1072909B/xx
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Priority to BR0307066-2A priority patent/BR0307066A/pt
Priority to NZ533694A priority patent/NZ533694A/en
Publication of WO2003061715A1 publication Critical patent/WO2003061715A1/en
Anticipated expiration legal-status Critical
Priority to NO20043494A priority patent/NO20043494L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment

Definitions

  • the invention relates generally to prohibiting microorganism infection associated with implanted medical devices.
  • the invention relates to the use of oxazolidinone compounds such as linezolid to prevent medical device-associated infections.
  • Oxazolidinones are a class of synthetic antibacterial agents. Oxazolidinone compounds are known in the art. In some embodiments, oxazolidinone compounds may have the formula:
  • X is a group selected from -CH 2 -NH-C(O)-R 4 , -CHA, and -CH2-Y-R4;
  • halo refers to a halogen atom selected from CI, Br, I, and F.
  • hetero refers to mono- or bi-cyclic ring systems containing at least one heteroatom selected from O, S, and N.
  • Each mono-cyclic ring may be aromatic, saturated, or partially unsaturated.
  • a bi-cyclic ring system may include a mono-cyclic ring contaimng at least one heteroatom fused with a cycloalkyl or aryl group.
  • a bi-cyclic ring system may also include a mono-cyclic ring containing at least one heteroatom fused with another het, mono-cyclic ring system.
  • R 5 at each occurrence is independently selected from the group consisting of H,
  • the concentration of the oxazolidinone compound in the human or animal body, adjacent to the medical device, that remains effective as an anti-adhesion agent is less than the MIC.
  • linezolid has been discovered to be surprisingly effective at preventing bacterial adhesion onto surfaces of biologically-compatible materials at concentrations below the
  • the device may be heated in an autoclave for sterilization prior to use, according to methods known to those skilled in the art (e.g., heating the device to a temperature of about 100 °C to about 121 °C; at a pressure of about 15 psi to about 20 psi; for a time period of about 15 min. to about 20 min.).
  • the amount of the oxazolidinone compound in the human or animal body or adjacent to the medical device that is effective as an anti-adhesion agent can be less than the MIC.
  • oxazolidinone compounds unexpectedly exhibit anti-adhesion properties at concentrations well below the MIC.
  • oxazolidinone compounds inhibit bacterial adhesion after a single dosing for longer periods of time relative to other antimicrobial agents which exhibit anti-adhesion properties at concentrations equal to or greater than the MIC.
  • Vancomycin a glycopeptide that inhibits bacterial cell wall synthesis
  • This assay is that bacterial cells adhere to polymeric material and to each other, forming a macrocolony whose density is measured spectrophotometrically after staining with crystal violet.
  • the reliability of this assay was assessed with adherent and nonadherent staphylococci reference strains and verified by image analysis using scanning electron microscopy.
  • linezolid was shown to be surprisingly effective in preventing staphylococcal adherence and colonization at subtherapeutic levels (i.e., concentrations of less than the minimum inhibitory concentration (MIC)).
  • MIC minimum inhibitory concentration
  • Example 1 Bacterial Isolates Staphylococci isolates were obtained from the blood of patients with catheter-related sepsis. Isolates were speciated using the API STAPH identification system (bioMerieux, Marcy-l'Etoile, France) and were selected on the basis of their adherence properties.
  • the reference strains S. epidermidis RP62A and S. hominis SP-2 were obtained from the American Type Culture Collection (Manassas, Virginia). RP62A produces polysaccharide adhesins and demonstrates strong adherence to surfaces of synthetic polymers. SP-2 is a nonadherent strain and was used as a negative control for the adherence assay.
  • Specimens were dehydrated in a series of aqueous ethanol solutions (30% - 100%) followed by critical point drying with hexamethydisilazane. The slides were allowed to dry overnight and then were coated with gold by using a Polaron E5200 SEM autocoating unit (Polaron Instruments). Microcolonies were examined by using an ISI DS 130 scanning electron microscope.
  • epidermidis RP62A adherent to a polystyrene surface (A) noninfected control; (B) infected-nontreated control; (C) infected culture treated with linezolid at one-fourth the MIC; and (D) infected culture treated with vancomycin at one-fourth the MIC.
  • adhesin proteins were observed on the cell surface of strain UC-20205, whereas RP62A displayed multiple layers of sessile cells that adhered to the polymer surface as well as to each other. Cell aggregation in multicell layers, "sessile communities," is indicative of biofilm formation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PCT/US2003/001710 2002-01-22 2003-01-21 Infection-resistant medical devices Ceased WO2003061715A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA04007067A MXPA04007067A (es) 2002-01-22 2003-01-21 Dispositivos medicos resistentes a infecciones.
KR10-2004-7011249A KR20040077753A (ko) 2002-01-22 2003-01-21 항감염성 의료 장치
CA002469665A CA2469665A1 (en) 2002-01-22 2003-01-21 Infection-resistant medical devices
EP03732006A EP1467773A1 (en) 2002-01-22 2003-01-21 Infection-resistant medical devices
HK05105508.9A HK1072909B (en) 2002-01-22 2003-01-21 Infection-resistant medical devices
JP2003561656A JP2005515029A (ja) 2002-01-22 2003-01-21 感染症耐性医療機器
BR0307066-2A BR0307066A (pt) 2002-01-22 2003-01-21 Dispositivo médico resistente a infecção
NZ533694A NZ533694A (en) 2002-01-22 2003-01-21 Infection-resistant medical devices
NO20043494A NO20043494L (no) 2002-01-22 2004-08-20 Infeksjonsresistent medisinsk innretning

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35076702P 2002-01-22 2002-01-22
US60/350,767 2002-01-22
US38065602P 2002-05-15 2002-05-15
US60/380,656 2002-05-15

Publications (1)

Publication Number Publication Date
WO2003061715A1 true WO2003061715A1 (en) 2003-07-31

Family

ID=27616780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001710 Ceased WO2003061715A1 (en) 2002-01-22 2003-01-21 Infection-resistant medical devices

Country Status (14)

Country Link
US (1) US7322965B2 (enExample)
EP (1) EP1467773A1 (enExample)
JP (1) JP2005515029A (enExample)
KR (1) KR20040077753A (enExample)
CN (1) CN1301751C (enExample)
BR (1) BR0307066A (enExample)
CA (1) CA2469665A1 (enExample)
CO (1) CO5611101A2 (enExample)
MX (1) MXPA04007067A (enExample)
NO (1) NO20043494L (enExample)
NZ (1) NZ533694A (enExample)
PL (1) PL371335A1 (enExample)
RU (1) RU2314831C2 (enExample)
WO (1) WO2003061715A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7322965B2 (en) 2002-01-22 2008-01-29 Pharmacia & Upjohn Company Infection-resistant medical devices

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200420573A (en) * 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
KR20060002800A (ko) * 2003-03-05 2006-01-09 립-엑스 파마슈티칼즈, 인크. 이관능성 헤테로시클릭 화합물, 및 그의 제조 및 사용 방법
WO2004084973A2 (en) * 2003-03-24 2004-10-07 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
EP1682563A1 (en) * 2003-10-30 2006-07-26 Rib-X Pharmaceuticals, Inc. Bifunctional macrolide heterocyclic compounds and mehtods of making and using the same
EP1699808A1 (en) * 2003-11-18 2006-09-13 Rib-X Pharmaceuticals, Inc. Bifunctional macrolide heterocyclic compounds and methods of making and using the same
US8202843B2 (en) 2004-02-27 2012-06-19 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
US8512294B2 (en) * 2006-07-28 2013-08-20 Becton, Dickinson And Company Vascular access device antimicrobial materials and solutions
US20090024096A1 (en) * 2007-07-20 2009-01-22 Baxter International Inc. Immobilization of dyes and antimicrobial agents on a medical device
US8460229B2 (en) 2007-08-17 2013-06-11 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states
US20090163964A1 (en) * 2007-08-17 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System, devices, and methods including sterilizing excitation delivery implants with general controllers and onboard power
US20090163977A1 (en) * 2007-08-17 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System, devices, and methods including sterilizing excitation delivery implants with cryptographic logic components
US20090177254A1 (en) * 2007-08-17 2009-07-09 Searete Llc, A Limited Liability Of The State Of The State Of Delaware System, devices, and methods including actively-controllable electrostatic and electromagnetic sterilizing excitation delivery system
US8162924B2 (en) 2007-08-17 2012-04-24 The Invention Science Fund I, Llc System, devices, and methods including actively-controllable superoxide water generating systems
US20090048648A1 (en) * 2007-08-17 2009-02-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Self-sterilizing device
US8647292B2 (en) * 2007-08-17 2014-02-11 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states
US8734718B2 (en) * 2007-08-17 2014-05-27 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US8753304B2 (en) * 2007-08-17 2014-06-17 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
US8706211B2 (en) * 2007-08-17 2014-04-22 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having self-cleaning surfaces
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US8702640B2 (en) * 2007-08-17 2014-04-22 The Invention Science Fund I, Llc System, devices, and methods including catheters configured to monitor and inhibit biofilm formation
US20110160644A1 (en) * 2007-08-17 2011-06-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including catheters configured to release ultraviolet energy absorbing agents
US20120041285A1 (en) 2008-12-04 2012-02-16 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including implantable devices with anti-microbial properties
US20110152751A1 (en) * 2008-12-04 2011-06-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including catheters having UV-Energy emitting coatings
EP2384168B1 (en) * 2008-12-04 2014-10-08 Searete LLC Actively-controllable sterilizing excitation delivery implants
US8585627B2 (en) * 2008-12-04 2013-11-19 The Invention Science Fund I, Llc Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure
US8821455B2 (en) * 2009-07-09 2014-09-02 Becton, Dickinson And Company Antimicrobial coating for dermally invasive devices
US20110065798A1 (en) * 2009-09-17 2011-03-17 Becton, Dickinson And Company Anti-infective lubricant for medical devices and methods for preparing the same
US9750928B2 (en) 2013-02-13 2017-09-05 Becton, Dickinson And Company Blood control IV catheter with stationary septum activator
US9695323B2 (en) 2013-02-13 2017-07-04 Becton, Dickinson And Company UV curable solventless antimicrobial compositions
US9327095B2 (en) 2013-03-11 2016-05-03 Becton, Dickinson And Company Blood control catheter with antimicrobial needle lube
US9750927B2 (en) 2013-03-11 2017-09-05 Becton, Dickinson And Company Blood control catheter with antimicrobial needle lube
US9789279B2 (en) 2014-04-23 2017-10-17 Becton, Dickinson And Company Antimicrobial obturator for use with vascular access devices
US10376686B2 (en) 2014-04-23 2019-08-13 Becton, Dickinson And Company Antimicrobial caps for medical connectors
US9675793B2 (en) 2014-04-23 2017-06-13 Becton, Dickinson And Company Catheter tubing with extraluminal antimicrobial coating
US10232088B2 (en) 2014-07-08 2019-03-19 Becton, Dickinson And Company Antimicrobial coating forming kink resistant feature on a vascular access device
CA3002633A1 (en) * 2015-08-18 2017-02-23 Cormedix Inc. Antimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same
US10493244B2 (en) 2015-10-28 2019-12-03 Becton, Dickinson And Company Extension tubing strain relief
CN108367097A (zh) 2015-12-19 2018-08-03 心脏起搏器股份公司 用于可植入医疗装置的生物惰性涂层
US10335513B2 (en) 2016-06-16 2019-07-02 Cardiac Pacemakers, Inc. Hydrophilization and antifouling of enhanced metal surfaces
US11324860B2 (en) 2016-08-09 2022-05-10 Cardiac Pacemakers, Inc. Durable antimicrobial layer for implantable medical devices
CN109414525A (zh) 2016-08-09 2019-03-01 心脏起搏器股份公司 用于可植入医疗装置的官能化的peg
WO2018112058A1 (en) 2016-12-18 2018-06-21 Cardiac Pacemakers, Inc. Infection fighting drug eluting lead boot
US10518004B2 (en) 2016-12-18 2019-12-31 Cardiac Pacemakers, Inc. Infection fighting drug eluting device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021636A1 (en) * 1994-02-15 1995-08-17 Gruppo Lepetit S.P.A. Central venous catheters loaded with antibiotics of the ramoplanin group preventing development of catheter related infections
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1998046287A2 (en) * 1997-04-15 1998-10-22 Uroteq Inc. Drug delivery via therapeutic hydrogels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4723950A (en) * 1984-12-12 1988-02-09 C. R. Bard, Inc. Urine drainage bag outlet with barrier against microbial infection
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US20050222632A1 (en) 1992-05-17 2005-10-06 Obino Stan F Device and method for the treatment of cardiac disorders
ATE181735T1 (de) 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5624704A (en) * 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
DE19707628A1 (de) * 1997-02-26 1998-08-27 Merck Patent Gmbh Oxazolidinone
US6719991B2 (en) * 2000-06-09 2004-04-13 Baylor College Of Medicine Combination of antimicrobial agents and bacterial interference to coat medical devices
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
EP1409464A4 (en) 2001-07-16 2005-11-02 Ranbaxy Lab Ltd OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS
NZ533694A (en) 2002-01-22 2006-08-31 Pharmacia & Upjohn Co Llc Infection-resistant medical devices
EA200500283A1 (ru) 2002-07-29 2005-08-25 Рэнбакси Лабораториз Лимитед Производные оксазолидинона как противомикробные средства

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021636A1 (en) * 1994-02-15 1995-08-17 Gruppo Lepetit S.P.A. Central venous catheters loaded with antibiotics of the ramoplanin group preventing development of catheter related infections
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1998046287A2 (en) * 1997-04-15 1998-10-22 Uroteq Inc. Drug delivery via therapeutic hydrogels

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"LINEZOLID. OXAZOLIDINONE ANTIBACTERIAL", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 21, no. 11, 1996, pages 1116 - 1123, XP000654643, ISSN: 0377-8282 *
PARADISI FRANCO ET AL: "Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics.", MEDICAL CLINICS OF NORTH AMERICA, vol. 85, no. 1, January 2001 (2001-01-01), pages 1 - 17, XP009010170, ISSN: 0025-7125 *
RAAD ISSAM ET AL: "Staphylococcus epidermidis: Emerging resistance and need for alternative agents.", CLINICAL INFECTIOUS DISEASES, vol. 26, no. 5, May 1998 (1998-05-01), pages 1182 - 1187, XP009010183, ISSN: 1058-4838 *
ZERAH G ET AL: "PREVENTION OF INFECTION RELATED TO PACEMAKER IMPLANTATION USING LASER SURGERY AND PROPHYLACTIC ANTIBIOTICS IN A SERIES OF 1184 PATIENTS", PACE - PACING AND CLINICAL ELECTROPHYSIOLOGY, FUTURA PUBLISHING COMPANY, INC, US, vol. 20, no. 9, PART 2, 1 September 1997 (1997-09-01), pages 2337, XP000704974, ISSN: 0147-8389 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7322965B2 (en) 2002-01-22 2008-01-29 Pharmacia & Upjohn Company Infection-resistant medical devices

Also Published As

Publication number Publication date
US20030176848A1 (en) 2003-09-18
EP1467773A1 (en) 2004-10-20
MXPA04007067A (es) 2004-11-01
JP2005515029A (ja) 2005-05-26
CO5611101A2 (es) 2006-02-28
NZ533694A (en) 2006-08-31
BR0307066A (pt) 2004-12-28
RU2314831C2 (ru) 2008-01-20
RU2004125584A (ru) 2005-04-20
CN1617746A (zh) 2005-05-18
HK1072909A1 (en) 2005-09-16
CN1301751C (zh) 2007-02-28
US7322965B2 (en) 2008-01-29
CA2469665A1 (en) 2003-07-31
NO20043494L (no) 2004-08-20
KR20040077753A (ko) 2004-09-06
PL371335A1 (en) 2005-06-13

Similar Documents

Publication Publication Date Title
US7322965B2 (en) Infection-resistant medical devices
DK2651419T3 (en) A composition comprising an antibiotic and a dispersant
EP3509598B1 (en) New use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
EP2296476A1 (en) Inhibitors of bacterial biofilm formation
OA11169A (en) Pharmaceutical compositions of tizoxanide and nitazoxanide
AU2003237472A1 (en) Infection-resistant medical devices
Pagano et al. Effects of linezolid on staphylococcal adherence versus time of treatment
HK1072909B (en) Infection-resistant medical devices
Henriques et al. Influence of sub-inhibitory concentrations of antimicrobial agents on biofilm formation in indwelling medical devices
KRISTINSSON et al. Coagulase-Negative Staphylococci–Pathogenesis and Microbial Diagnosis
BR112019003661B1 (pt) Usos de derivados de triazolo(4,5-d) pirimidina, e método para neutralização de bactérias ou prevenção do crescimento bacteriano na formação de biofilme
HK1220911B (en) A composition comprising a non-peptide antibiotic and cysteamine
HK1185015B (en) A composition comprising an antibiotic and a dispersant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2469665

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003237472

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003732006

Country of ref document: EP

Ref document number: 1717/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 533694

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003561656

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004/05335

Country of ref document: ZA

Ref document number: 200405335

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003802392X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 163081

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501086

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1020047011249

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007067

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1200400722

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2004125584

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2003732006

Country of ref document: EP